Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data IRIDEX CORP files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2026
Revenue
46.2
41.6
42.6
43.4
36.3
53.9
57
51.9
48.7
52.7
Cost of revenue
25.3
26.1
25.1
25.5
20.8
31.1
31.6
30.1
29.2
33.4
Gross profit
20.8
15.5
17.5
17.9
15.6
22.8
25.4
21.8
19.5
19.2
Research and development
5.37
5.21
4.01
3.68
3.28
6.87
7.18
6.83
5.45
3.67
Selling and marketing
10.3
14.5
16.8
14.9
12.2
14.6
18.2
16.2
12.6
10.4
General and administrative
7.64
8.78
9.55
8.38
6.62
8.86
7.56
8.75
9.78
7.73
Operating expenses
23.4
28.4
30.3
26.9
22.1
30.4
32.9
31.8
27.8
21.8
Operating income
-2.57
-12.9
-12.9
-8.97
-6.58
-7.53
-7.54
-10
-8.3
-2.57
Interest expense
0.15
0.06
Other non-operating income
-0.09
-0.11
0.09
0.21
0.28
2.35
0.06
0.53
-0.54
-1.81
Pre-tax income
-2.66
-13
-12.8
-8.77
-6.3
-5.19
-7.48
-9.48
-8.84
-4.38
Income tax
9.06
-0.13
0.04
0.05
0.03
0.04
0.07
0.09
0.07
0.06
Net income
-11.7
-12.9
-12.8
-8.81
-6.33
-5.23
-7.55
-9.57
-8.91
-4.44
EBITDA
-1.92
-12
-12.1
-8.29
-6.08
-6.73
-7.06
-8.91
-7.72
-2.05
EPS, basic
-1.15
-1.11
-1.05
-0.64
-0.46
-0.34
-0.47
-0.59
-0.54
-0.26
EPS, diluted
-1.15
-1.11
-1.05
-0.64
-0.46
-0.34
-0.47
-0.59
-0.54
-0.26
Shares, basic (weighted)
10.2
11.6
12.2
13.7
13.8
15.4
15.9
16.1
16.4
16.9
Shares, diluted (weighted)
10.2
11.6
12.2
13.7
13.8
15.4
15.9
16.1
16.4
16.9
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2026
Cash and equivalents
23.7
21.7
21.2
12.7
11.6
23.9
13.9
7.03
2.39
6.03
Receivables
10
7.86
9.08
9.32
7.29
6.61
6.23
6.73
5.95
7.61
Inventory
11.6
9.38
8.79
8.17
5.71
7.61
10.6
9.91
10.8
7.88
Other current assets
0.45
0.5
0.55
0.4
0.73
1.07
1.47
0.86
1.96
1.8
Total current assets
45.9
39.5
39.6
30.6
25.4
42.3
35.8
27.5
23.6
25.3
Property, plant and equipment
1.53
1.4
1.22
0.73
0.45
0.43
0.46
0.35
0.12
0.06
Lease right-of-use assets
2.76
1.43
2.57
1.67
2.63
1.79
0.77
Goodwill
0.53
0.53
0.53
0.53
0.53
0.97
0.97
0.97
0.97
0.97
Intangible assets
0.13
0.12
0.1
0.08
0.07
2.21
1.98
1.64
1.31
0.98
Other non-current assets
0.08
0.14
0.2
0.15
0.13
0.27
1.46
1.4
1.39
1.12
Total assets
48.1
41.6
41.7
34.8
28
48.7
42.3
34.4
29.1
29.2
Accounts payable
1.99
1.72
2.52
2.59
1.15
2.77
3.86
4.5
6.99
5.39
Accrued liabilities
2.14
2.15
2.76
1.54
0.99
1.58
1.55
2
0.48
0.61
Deferred revenue
1.38
2.52
1.64
1.45
0.94
2.36
2.41
2.4
2.18
2.16
Short-term debt
1.25
1.7
Total current liabilities
8.17
10.4
10.5
9.78
8.68
12.6
12.5
13
16.6
13.2
Lease liabilities
1.8
0.28
1.73
0.73
1.75
0.81
0.1
Other non-current liabilities
0.52
0.53
0.39
0.02
0.02
0.03
0.03
0.16
0.31
0.39
Total liabilities
8.98
11.1
11.7
12.1
10.6
25.4
25.1
24.9
27
24.2
Total debt
1.25
1
Paid-in capital
55.2
59.4
71.5
73.1
74.2
85.3
86.8
88.4
89.9
91.2
Retained earnings
-16.1
-29
-41.8
-50.6
-56.9
-62.2
-69.7
-79
-88
-92.4
Other comprehensive income
0.07
0.08
-0.02
0.05
-0.02
-0.05
0.05
-0.01
Shareholders' equity
39.2
30.5
30
22.7
17.4
23.3
17.2
9.52
2.1
4.92
Total equity
39.2
30.5
30
22.7
17.4
23.3
17.2
9.52
2.1
4.92
Total liabilities and equity
48.1
41.6
41.7
34.8
28
48.7
42.3
34.4
29.1
29.2
Shares outstanding
11.3
11.6
13.6
13.8
13.9
15.9
16
16.3
16.6
17.3
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2021
FY2021
FY2022
FY2023
FY2024
FY2026
Net income
-11.7
-12.9
-12.8
-8.81
-6.33
-5.23
-7.55
-9.57
-8.91
-4.44
Depreciation and amortization
0.65
0.86
0.81
0.69
0.5
0.8
0.49
1.1
0.58
0.52
Stock-based compensation
1.82
1.92
1.8
1.7
1.12
1.63
1.62
1.65
1.24
0.78
Deferred income tax
8.99
Change in receivables
-0.87
2.16
-1.16
-0.27
1.86
0.64
0.2
-0.25
0.78
-1.66
Change in inventory
-0.54
2.09
0.46
0.55
2.38
0.27
-3.02
0.64
-0.91
2.12
Change in payables
-0.23
-0.27
0.79
0.08
-1.45
1.63
1.09
0.64
2.49
-1.95
Cash from operations
-0.14
-3.57
-10
-7.91
-3.24
8.22
-9.52
-6.75
-7.29
-2.12
Capital expenditures
-1.06
-0.58
-0.44
-0.13
-0.1
-0.21
-0.29
-0.11
-0.01
-0.14
Acquisitions
-5.34
0
Cash from investing
-1.47
-0.78
-0.83
-0.51
-0.09
-5.56
-0.29
-0.11
-0.01
-0.14
Debt issued
2.5
Stock issued
14.8
2.26
10.5
9.88
0
0.08
0
0
Share buybacks
-0.06
Cash from financing
15.4
2.31
10.4
-0.16
2.47
9.47
-0.07
-0.01
2.61
5.96
Net change in cash
13.8
-2.04
-0.51
-8.54
-1.03
12.2
-9.93
-6.89
-4.65
3.64
Free cash flow
-1.21
-4.14
-10.5
-8.04
-3.33
8
-9.81
-6.85
-7.3
-2.26
Income taxes paid
0.02
0.01
0.01
0.01
-0.07
0.02
0.07
0.05
0.02
-0.02
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to July 4, 2026; growth uses fiscal years. Valuation uses the share price of $0.63 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
35.9%
Gross profit / revenue.
Operating margin
-5.4%
Operating income / revenue.
EBITDA margin
-4.5%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-6.6%
Pre-tax income / revenue.
Net margin
-6.9%
Net income / revenue.
FCF margin
-3.9%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-3.4%
Cash from operations / revenue.
Return on equity (ROE)
-97.5%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-13.0%
Net income / average total assets.
R&D / revenue
7.3%
Research and development expense / revenue.
Stock-based pay / revenue
1.4%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.5%
Capital expenditures / revenue.
D&A / revenue
0.9%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
8.2%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-2.6%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
7.7%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-1.4%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-8.8%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
4.3%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
134.7%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-34.1%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-22.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
0.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-11.7%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
0.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
3.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
2.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
4.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.82x
Current assets / current liabilities.
Quick ratio
0.79x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.36x
(Cash + short-term investments) / current liabilities.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.20
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$2.96
Revenue / diluted weighted shares.
FCF per share
-$0.11
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.10
Cash from operations / diluted weighted shares.
Book value per share
$0.21
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.21x
Market cap / revenue.
P/B
2.99x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
5.88x
Market cap / tangible book value, when positive.
EV/Sales
0.12x
Enterprise value / revenue.
FCF yield
-18.4%
Free cash flow / market cap.
Earnings yield
-32.6%
Net income / market cap (the inverse of P/E).
What was IRIDEX CORP's revenue in fiscal 2026?
IRIDEX CORP reported revenue of $52.7M for fiscal 2026, 8.2% higher than the year before.
Was IRIDEX CORP profitable in fiscal 2026?
No. It reported a net loss of $4.4M.
How much free cash flow did IRIDEX CORP generate in fiscal 2026?
Cash from operations of $2.1M minus capital expenditures of $143.0K left free cash flow of -$2.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.